These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34597343)

  • 41. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
    Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
    Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.
    Reeves AE; Theriot CM; Bergin IL; Huffnagle GB; Schloss PD; Young VB
    Gut Microbes; 2011; 2(3):145-58. PubMed ID: 21804357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota.
    Fletcher JR; Pike CM; Parsons RJ; Rivera AJ; Foley MH; McLaren MR; Montgomery SA; Theriot CM
    Nat Commun; 2021 Jan; 12(1):462. PubMed ID: 33469019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition.
    Rousseau C; Levenez F; Fouqueray C; Doré J; Collignon A; Lepage P
    J Clin Microbiol; 2011 Mar; 49(3):858-65. PubMed ID: 21177896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus.
    Engevik MA; Danhof HA; Auchtung J; Endres BT; Ruan W; Bassères E; Engevik AC; Wu Q; Nicholson M; Luna RA; Garey KW; Crawford SE; Estes MK; Lux R; Yacyshyn MB; Yacyshyn B; Savidge T; Britton RA; Versalovic J
    Gastroenterology; 2021 Mar; 160(4):1301-1314.e8. PubMed ID: 33227279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bacteria producing antimicrobials against Clostridium difficile isolated from human stool.
    Khattab RA; Ahmed NA; Ragab YM; Rasmy SA
    Anaerobe; 2020 Jun; 63():102206. PubMed ID: 32339663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
    Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
    mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of
    Rueedi G; Panchaud P; Friedli A; Specklin JL; Hubschwerlen C; Blumstein AC; Caspers P; Enderlin-Paput M; Jacob L; Kohl C; Locher HH; Pfaff P; Schmitt C; Seiler P; Ritz D
    J Med Chem; 2024 Jun; 67(11):9465-9484. PubMed ID: 38753983
    [No Abstract]   [Full Text] [Related]  

  • 49. An Integrated Metabolomic and Microbiome Analysis Identified Specific Gut Microbiota Associated with Fecal Cholesterol and Coprostanol in Clostridium difficile Infection.
    Antharam VC; McEwen DC; Garrett TJ; Dossey AT; Li EC; Kozlov AN; Mesbah Z; Wang GP
    PLoS One; 2016; 11(2):e0148824. PubMed ID: 26871580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection.
    Normington C; Moura IB; Bryant JA; Ewin DJ; Clark EV; Kettle MJ; Harris HC; Spittal W; Davis G; Henn MR; Ford CB; Wilcox MH; Buckley AM
    NPJ Biofilms Microbiomes; 2021 Feb; 7(1):16. PubMed ID: 33547298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microbiota in vitro modulated with polyphenols shows decreased colonization resistance against Clostridioides difficile but can neutralize cytotoxicity.
    Mahnic A; Auchtung JM; Poklar Ulrih N; Britton RA; Rupnik M
    Sci Rep; 2020 May; 10(1):8358. PubMed ID: 32433519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases.
    Dutta D; Jafri F; Stuhr D; Knoll BM; Lim SH
    J Intern Med; 2021 Mar; 289(3):293-308. PubMed ID: 32910532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.
    Zhang L; Dong D; Jiang C; Li Z; Wang X; Peng Y
    Anaerobe; 2015 Aug; 34():1-7. PubMed ID: 25817005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies.
    De Wolfe TJ; Kates AE; Barko L; Darien BJ; Safdar N
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
    Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
    Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
    Sears P; Crook DW; Louie TJ; Miller MA; Weiss K
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S116-20. PubMed ID: 22752859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrating gut microbiome and host immune markers to understand the pathogenesis of
    Ke S; Pollock NR; Wang XW; Chen X; Daugherty K; Lin Q; Xu H; Garey KW; Gonzales-Luna AJ; Kelly CP; Liu YY
    Gut Microbes; 2021; 13(1):1-18. PubMed ID: 34132169
    [No Abstract]   [Full Text] [Related]  

  • 58. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls.
    Schubert AM; Rogers MA; Ring C; Mogle J; Petrosino JP; Young VB; Aronoff DM; Schloss PD
    mBio; 2014 May; 5(3):e01021-14. PubMed ID: 24803517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
    Lv Z; Peng G; Liu W; Xu H; Su J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.
    Phanchana M; Phetruen T; Harnvoravongchai P; Raksat P; Ounjai P; Chankhamhaengdecha S; Janvilisri T
    Sci Rep; 2020 Apr; 10(1):6497. PubMed ID: 32300130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.